Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK Paxil CR Ad Medicalizes “Ordinary” Anxiety, FDA Says

Executive Summary

GlaxoSmithKline Paxil CR TV ads suggest the antidepressant is appropriate for treating anxiety that does not require medication, FDA's ad division says

You may also be interested in...

GSK Posts Paxil Pediatric Data On Website; Plans U.S. Clinical Trial Register

GlaxoSmithKline's off-the-shelf response to requests for information about off-label use of Paxil in pediatric patients notes that there are studies demonstrating efficacy of paroxetine in obsessive/compulsive disorder and social anxiety disorder

Paxil Fraud Case May Spur Congressional, FDA Action – Schering Exec

Fallout from GlaxoSmithKline's handling of Paxil pediatric studies may lead to increased pressure by Congress or FDA for greater disclosure, Schering-Plough Senior VP-Global Compliance & Business Practices Brenton Saunders said

Wyeth Effexor Claim Of Superiority To SSRIs Challenged; Radio Ad Also Cited

FDA is challenging Wyeth Effexor/Effexor XR promotions that suggest the antidepressant is more effective than SSRIs

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts